FDA Panel Fails To Back Abuse-deterrent Properties Of KemPharm's Pain Pill

The FDA panel vote on KemPharm Inc's (KMPH) Apadaz, an investigational abuse-deterrent product candidate for the short-term management of acute pain, has come as a dampener for the company.

from RTT - Biotech http://ift.tt/24vFECC
via IFTTT